Pinsky Brett, Harnett James, Paulose-Ram Ryne, Mardekian Jack, Samant Navendu, Nair Kavita V
Senior Researcher, OptumInsight, Eden Prairie, MN.
Senior Director, US Health Economics and Outcomes Research, Pfizer, NY.
Am Health Drug Benefits. 2011 Nov;4(7):429-38.
The National Committee for Quality Assurance supports high-quality care for patients through the Diabetes Recognition Program (DRP). The DRP recognizes physicians and practices that are providing high-quality diabetes care as determined by 10 key measures.
To examine the impact of treatment by DRP-certified physicians compared with non-DRP-certified physicians on patient outcomes.
This retrospective claims analysis was conducted from January 1, 2007, through November 30, 2007, using a large US database of approximately 14 million commercially insured members. Physicians with DRP certification (N = 1188) were identified and matched 1:1 to physicians without DRP certification based on physician specialty, location (state) of practice, size of potential patient population, and number of patients with type 2 diabetes treated by the physician. Patients were included if they had type 2 diabetes and had been treated by a physician in the DRP group (N = 3836) or in the comparison group (N = 4175). Primary outcomes were medication use, medical resource utilization, and expenditures. Per-patient per-year (PPPY) medical and pharmacy utilization measures were analyzed using Poisson regression; PPPY expenditures were estimated using a generalized linear model with gamma distribution.
Multivariate analysis showed that patients treated by DRP-certified physicians had more postindex diabetes-related office visits (mean PPPY, 4.69 vs 4.44, respectively; P <.001) and outpatient visits (mean PPPY, 0.93 vs 0.85, respectively; P <.001) than patients treated by non-DRP-certified physicians, but fewer emergency department visits (mean PPPY, 0.04 vs 0.07, respectively; P <.001) and inpatient visits (mean PPPY, 0.08 vs 0.10, respectively; P = .02). Prescribing rates for oral antihyperglycemic drugs and statins were higher among DRP-certified physicians than non-DRP-certified physicians. Total diabetes-related healthcare expenditures were lower for patients with type 2 diabetes managed by DRP-certified physicians compared with those managed by non-DRP-certified physicians (mean PPPY, $3424 vs $4097, respectively; P = .03).
Significant differences in oral antihyperglycemic and statin drug use, and diabetes-related emergency department and inpatient visits and expenditures, were observed in this study between DRP-certified and non-DRP-certified physicians, showing overall improved outcomes for patients managed by DRP-certified physicians.
国家质量保证委员会通过糖尿病认可计划(DRP)支持为患者提供高质量护理。DRP认可那些通过10项关键指标判定为提供高质量糖尿病护理的医生和医疗机构。
研究与未获得DRP认证的医生相比,获得DRP认证的医生的治疗对患者治疗结果的影响。
本回顾性索赔分析于2007年1月1日至2007年11月30日进行,使用了一个包含约1400万商业保险会员的大型美国数据库。确定了获得DRP认证的医生(N = 1188),并根据医生专业、执业地点(州)、潜在患者群体规模以及医生治疗的2型糖尿病患者数量,将其与未获得DRP认证的医生进行1:1匹配。如果患者患有2型糖尿病且接受了DRP组(N = 3836)或对照组(N = 4175)中医生的治疗,则将其纳入研究。主要结局指标为药物使用、医疗资源利用和费用支出。使用泊松回归分析每位患者每年(PPPY)的医疗和药房利用指标;使用具有伽马分布的广义线性模型估计PPPY费用。
多变量分析显示,与未获得DRP认证的医生治疗的患者相比,获得DRP认证的医生治疗的患者在索引后糖尿病相关门诊就诊次数更多(平均PPPY分别为4.69次和4.44次;P <.001),门诊就诊次数也更多(平均PPPY分别为0.93次和0.85次;P <.001),但急诊就诊次数更少(平均PPPY分别为0.04次和0.07次;P <.001),住院就诊次数更少(平均PPPY分别为0.08次和0.10次;P =.02)。获得DRP认证的医生开具口服降糖药和他汀类药物的比例高于未获得DRP认证的医生。与未获得DRP认证的医生管理的2型糖尿病患者相比,获得DRP认证的医生管理的患者的糖尿病相关总医疗费用更低(平均PPPY分别为3424美元和4097美元;P =.03)。
本研究观察到,获得DRP认证和未获得DRP认证的医生在口服降糖药和他汀类药物使用、糖尿病相关急诊就诊和住院就诊及费用方面存在显著差异,表明获得DRP认证的医生管理的患者总体治疗结果有所改善。